
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7B
Deals and Financings Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA (OTCPK:MKGAF) for a $170 million